{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-301520","form_type":"8-K","ticker":"QTTB","cik":"0001661998","company_name":"Q32 Bio Inc.","filed_at":"2026-07-13T12:39:54+00:00","discovered_at":"2026-07-13T12:45:00.262421+00:00","generated_at":"2026-07-13T12:45:10.996891+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"low","headline":"Q32 Bio announces topline results from SIGNAL-AA Phase 2a Part B trial of bempikibart in alopecia areata","bullets":["Topline results from 36-week Part B of SIGNAL-AA Phase 2a trial for bempikibart (ADX-914) in alopecia areata announced on July 13, 2026.","Presentation filed as Exhibit 99.1 contains detailed efficacy, safety, and biomarker data; no numerical results provided in the 8-K body.","Company cautions that additional data analyses may not support current beliefs; risks include trial costs, funding needs, and regulatory uncertainties.","Forward-looking statements highlight potential differences between topline and final results; stock may react to data in the exhibit."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-301520","json":"https://secwatch.observer/filing/0001193125-26-301520.json","markdown":"https://secwatch.observer/filing/0001193125-26-301520.md","text":"https://secwatch.observer/filing/0001193125-26-301520.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661998/000119312526301520/0001193125-26-301520-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661998/000119312526301520/d143274d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-13T12:45:10.996891+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}